Exscientia to Report Second Quarter 2023 Financial Results on August 10, 2023Business Wire • 08/03/23
First Patient Enrolled in Phase 1/2 “ELUCIDATE” Trial Assessing GTAEXS617 in Advanced Solid TumoursBusiness Wire • 07/10/23
Exscientia to Present at the Goldman Sachs 44th Annual Global Healthcare ConferenceBusiness Wire • 06/06/23
Exscientia Highlights "The Future of AI-enabled Drug Discovery" at SLAS EuropeBusiness Wire • 05/22/23
Exscientia's AI-Powered Drug Discovery Platform Is The Future Of Precision MedicineSeeking Alpha • 05/18/23